Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 13,734 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Lymphoma
Interventions: filgrastim, gemcitabine hydrochloride, vinorelbine tartrate; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 108
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 93 more

Conditions: Chronic Kidney Disease, Proteinuria, Children
Interventions: Finerenone (Kerendia, BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more

Conditions: HCC
Interventions: GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012; Biological · Device
Lead sponsor: Geneos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more

Conditions: Breast Cancer
Interventions: Placebo, Denosumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 4,509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 93
States / cities: Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 81 more

Conditions: Duchenne Muscular Dystrophy
Interventions: HT-100; Drug
Lead sponsor: Processa Pharmaceuticals; Industry
Eligibility: 6 Years to 20 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Tobacco Dependence
Interventions: C-Raven Virtual Tobacco Cessation Counseling, Nicotine Replacement Product, Community Health Worker, Lung Cancer Screening; Behavioral · Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 18
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 12 more

Conditions: Gender-based Violence
Interventions: Women and Child, Safety, Health and Empowerment (WC-SHE); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Clostridioides Difficile Infection
Interventions: Ridinilazole, Vancomycin; Drug
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 49
States / cities: Birmingham, Alabama • Sun City, Arizona • Los Angeles, California + 45 more

Conditions: Chronic Hepatitis C
Interventions: Daclatasvir (BMS-790052), Sofosbuvir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 16 more

Conditions: Infectious Diseases
Interventions: Chagas Detect Plus; Other
Lead sponsor: InBios International, Inc.; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fracture, Fractures, Bone, Fractures, Closed, Fractures, Open
Interventions: FastFrame External Fixation System - Knee Spanning or Damage Control Kit; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma, Gastric Intestinal Type Adenocarcinoma, Gastric Mixed Adenocarcinoma, Recurrent Gastric Carcinoma
Interventions: Akt Inhibitor MK2206; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 186
States / cities: Mobile, Alabama • Fairbanks, Alaska • Tucson, Arizona + 124 more

Conditions: Crohn's Disease
Interventions: natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 35
States / cities: Scottsdale, Arizona • Oceanside, California • San Francisco, California + 31 more

Conditions: Multiple Sclerosis (MS)
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: Not listed
Enrollment: 1,507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Baltimore, Maryland • St Louis, Missouri • Las Vegas, Nevada + 3 more

Conditions: MPN (Myeloproliferative Neoplasms)
Interventions: itacitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 14
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more

Conditions: Depressive Symptoms, Anxiety, Cancer
Interventions: psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteo Arthritis Knee
Interventions: U2 Knee™ System; Device
Lead sponsor: United Orthopedic Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 4
States / cities: Bradenton, Florida • Jacksonville, Florida • Vero Beach, Florida + 1 more

Conditions: Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage II Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions: adjuvant therapy, paclitaxel, carboplatin, bevacizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 17
States / cities: Orange, California • Chicago, Illinois • Iowa City, Iowa + 9 more

Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®); Genetic · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 107
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more

Conditions: Peanut Hypersensitivity
Interventions: Peanut Oral Immunotherapy - Liquid Extract, Placebo for Peanut Oral Immunotherapy - Liquid Extract form, Peanut Oral Immunotherapy - Peanut Flour, Placebo for Peanut Oral Immunotherapy - Peanut Flour; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Months to 48 Months
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 5
States / cities: Little Rock, Arkansas • Stanford, California • Baltimore, Maryland + 2 more

Conditions: Healthy
Interventions: Lisinopril, Zestril; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV-1-infection, Pregnancy, Postpartum
Interventions: CAB LA 600mg, RPV LA 900mg, CAB LA 400mg, RPV LA 600mg; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: La Jolla, California • Los Angeles, California • Baltimore, Maryland + 1 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Interventions: Dapagliflozin 10 mg, Placebo tablet; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 17,190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 234
States / cities: Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 202 more

Search by objective public record fields.

Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Open Label Extension Study of HT-100 in Patients With DMD

C-Raven, a Virtual Tobacco Cessation Intervention in Residency Clinics

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Women and Child, Safety, Health, and Empowerment

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

Specificity Study of Diagnostic for Chagas Disease

FastFrame Knee Spanning and Damage Control Kit PMCF

Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study

An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

Psychopharmacology of Psilocybin in Cancer Patients

Prospective Post Approval Clinical Follow-Up Study of the Commercially Available U2 Knee™ System - "U-Propel Study"

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Peanut Oral Immunotherapy in Children

Comparative Bioavailability Study of Lisinopril Tablets, 10 mg

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events